10.16.2017
Prevent & Delay
$2,031,407.00
33 months
Development of antigen-specific enhanced T-reg therapy in T1D
Funds support a work into a preclinical proof-of-principle for an engineered targeted Treg cell therapy to treat type 1 diabetes.